21 May 2009
New tools for defining immune stability in long-term recipients of kidney allograft
J SoulillouAnn Transplant 2009; 14(1): 12-12 :: ID: 880239
Abstract
The study of biological correlates associated with state of operational acceptance of mismatched kidney grafts years after of total interruption of immunosuppressive drugs on one side, and the growing information concerning biomarkers associated with chronic rejection may contribute to a better understanding of the status of "stable patients" years following transplantation. This understanding is crucial for guiding eventual minimalisation on weaning of immunosuppressive drugs. Recently, our laboratory has described several biological correlates with immunosuppressive drug free operational acceptance of kidney graft, including phenotypes and transcriptional alterations. Similarly, we have described a series of blood biomarkers increased (TLR4, Trib1, PSMB10) or decreased (granzyme B) in the blood of patients with chronic active rejection associated with DSA. Using these acceptance or rejection biomarkers, we screened a cohort of 164 patients presenting a highly stable clinical status at more than five years after transplantation. We show that these patients do not express the rejection associated set of biomarkers. However, according to the stringency of the analysis, few patients, of these patients under dual therapy, exhibit the operational acceptance signature (<5%). Longer follow up of these stable patients also show that a minority of them (~10%) have degraded their function with time. Grafts biopsies of these patients did not evidence chronic rejection symptom, excepted in one case but show aspecific lesions (toxicity, relapse or LAN). Despite this late degradation was not related to chronic rejection, DNAchips performed on these patients at the time of their highly stable status discriminated this outcome suggesting that an "aspecific" infl ammation status can be monitored. Collectively we hope that these data will set more scientific bases for protocols aimed at weaning CNI or other immunosuppressive drugs.
Keywords: immunosuppressive drugs, Transplantation
In Press
Original article
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...Ann Transplant In Press; DOI: 10.12659/AOT.953761
Clinical Research
Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cel...Ann Transplant In Press; DOI: 10.12659/AOT.954230
Clinical Research
Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response ...Ann Transplant In Press; DOI: 10.12659/AOT.954574
Most Viewed Current Articles
24 Aug 2021 : Review article 21,978
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 18,247
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,856
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,762
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






